EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

• DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST - – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs to date – – Full topline data anticipated in Q1 2025 – WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company commit ...